Advertisement

International Journal of Clinical Pharmacy

, Volume 35, Issue 2, pp 244–250 | Cite as

Evaluation of adherence to international guidelines for treating patients with type 2 diabetes mellitus in Kuwait

  • Dalal M. Al-Taweel
  • Abdelmoneim I. AwadEmail author
  • B. Julienne Johnson
Research Article

Abstract

Background Clinical guidelines derived from scientific evidence provide the basis of consistent standardized prescribing. Despite an alarming increase of diabetes in Kuwait, no studies related to the quality of prescribing in diabetes were found. Before pharmaceutical care can be implemented to improve the quality of care of patients with diabetes, it is important to determine whether prescribers are compliant with comprehensive international guidelines for cardioprevention and glycaemic control. Objective To evaluate the adherence to clinical guidelines for treating patients with type 2 diabetes mellitus in primary care centres and secondary care centres (hospitals) using a developed and validated medication assessment tool with reference to international guidelines. Setting Outpatient diabetes clinics in 8 primary care centres and 4 secondary care centres across four healthcare regions in Kuwait. Method A quantitative, cross-sectional study involving a sample of 652 Kuwaiti patients with type 2 diabetes, who were selected using systematic sampling from the study settings. Data were collected retrospectively from the patients’ medical records using a validated 43-criterion medication assessment tool (MATKW) designed to assess cardioprevention and treatment in patients with type 2 diabetes. Descriptive and comparative analysis was conducted using SPSS version 17. Main Outcome Measure Frequency of prescribing adherence to agreed definitions of criteria derived from international guidelines. Results Overall adherence to prescribing diabetes guidelines was 77.7 % (95 % CI 76.7–78.6 %). Significantly higher prescribing adherence was found in the secondary care facilities, 82.4 % (95 % CI 81.2–83.6 %) compared to primary care 72.5 % (95 % CI 71.0–73.9 %) (p < 0.001). Nineteen criteria out of 43 achieved an adherence >80 % in secondary care compared to ten criteria in primary care. The documentation of patients’ records was found to be inconsistent at the study healthcare facilities. Nonoptimal achievement of target goals for HbA1c, blood pressure and BMI was prevalent among the study population. Conclusion: A tool such as MATKW highlights areas for review and possible improvement in prescribing adherence. Our findings reveal problem areas in prescribing practices and documentation of patients’ records. Cost-effective multifaceted interventions are needed to improve current prescribing practices and documentation.

Keywords

Clinical guidelines Kuwait Pharmaceutical care Prescribing Type 2 diabetes 

Notes

Acknowledgments

We are grateful to all the physicians and the staff at the healthcare facilities for their assistance during data collection. The authors wish to acknowledge the contribution of the late Professor Steve Hudson (deceased) in the early stages of this work. We would also like to acknowledge Professor Lukman Thalib for his statistical advice. The MATKW is available on request by email from the corresponding author (amoneim@hsc.edu.kw).

Funding

None.

Conflicts of interest

None.

References

  1. 1.
    International Diabetes Federation: IDF Diabetes Atlas. http://www.idf.org/diabetesatlas/5e/the-global-burden Accessed 25 Jan 2012.
  2. 2.
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2009;32:S13–61.CrossRefGoogle Scholar
  3. 3.
    World Health Organization. Diabetes Fact sheet No 312. Department of chronic diseases and health promotion. http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed 25 Dec 2011).
  4. 4.
    Abdella N, Khogali M, Al-Ali S, Gumaa K, Bajaj J. Known Type 2 diabetes mellitus among the Kuwaiti population: a prevalence study. Acta Diabetol. 1996;33:145–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Advisory Commission on Health Consumer Protection and Quality in the Health Care Industry. Quality First: Better Health Care for All Americans. Washington: U.S. Government Printing Office; 1998.Google Scholar
  6. 6.
    Al-Adsani A, Al-Faraj J, Al-Sultan F, El-Feky M, Al-Mezel N, Saba W, Aljassar S. Evaluation of the impact of the Kuwait Diabetes Care Program on the quality of diabetes care. Med Princ Pract. 2008;17:14–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Hakonsen GD, Hudson S, Loennechen T. Design and validation of a medication assessment tool for cancer pain management. Pharm World Sci. 2006;28:342–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Hakonsen GD, Torbergsen AL, Strelec P, Cambell D, Hudson S, Loennechen T. A medication assessment tool to evaluate adherence to medication guideline criteria in cancer pain management. Int J Pharm Pract. 2008;16:99–107.CrossRefGoogle Scholar
  9. 9.
    Kamyar M, Johnson BJ, McAnaw J, Lemmens-Gruber R, Hudson S. Adherence to clinical guidelines in the prevention of coronary heart disease in type II diabetes mellitus. Pharm World Sci. 2008;30:120–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Lenth RV. Java applets for power and sample size [Computer software]; 2006–2009. http://www.stat.uiowa.edu/~rlenth/Power/. Accessed 17 Dec 2009.
  11. 11.
    Guidelines on diabetes, pre-diabetes and cardiovascular diseases: The Task Force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;9 (suppl C): C3–C74. doi:  10.1093/eurheartj/ehl261.
  12. 12.
    Scottish Intercollegiate Guidelines Network. Heart disease guidelines 93–97. http://www.sign.ac.uk/guidelines/fulltext/93-97/index.html. Accessed 10 Nov 2009.
  13. 13.
    National Institute for Health and Clinical Excellence. CG66 Type 2 diabetes: full guideline. http://www.nice.org.uk/guidance/index.jsp?action=download&o=40803. Accessed 2009 Nov 7.
  14. 14.
    Diab M, Towle I, Johnson BJ, Hudson S. The quality of medication use in obesity management and in primary prevention of cardiovascular disease (CVD). Pharm World Sci. 2010;32:241.Google Scholar
  15. 15.
    Khunti K, Ganguli S. Who looks after people with diabetes: primary or secondary care? J R Soc Med. 2000;93:183–6.PubMedGoogle Scholar
  16. 16.
    Miller R, Sim I. Physician’s use of electronic medical records: barriers and solutions. Health Aff. 2004;23:116–26.CrossRefGoogle Scholar
  17. 17.
    Laing RO, Hogerzeil HV, Ross-Degnan D. Ten recommendations to improve use of medicines in developing countries. Health Policy Plan. 2001;16:13–20.PubMedCrossRefGoogle Scholar
  18. 18.
    Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998;317:465–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Pringle M, Stewart-Evans C, Coupland C, Williams I, Allison S, Sterland J. Influences on control in diabetes mellitus: patient, doctor, practice or delivery of care? BMJ. 1993;306:630–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Whitley HP, Fermo JD, Ragucci K, Chumney EC. Assessment of patient knowledge of diabetic goals, self-reported medication adherence, and goal attainment. Pharm Pract. 2006;4:183–90.Google Scholar
  21. 21.
    Clifford RM, Davis WA, Batty KT, Davis TM. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2005;28:771–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Odegard PS, Goo A, Hummel J, Williams KL, Gray SL. Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Ann Pharmacother. 2005;39:433–40.PubMedCrossRefGoogle Scholar
  23. 23.
    Kiel PJ, McCord AD. Pharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice. Ann Pharmacother. 2005;39:1828–32.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Dalal M. Al-Taweel
    • 1
    • 2
  • Abdelmoneim I. Awad
    • 2
    Email author
  • B. Julienne Johnson
    • 1
  1. 1.Strathclyde Institute of Pharmacy and Biomedical ScienceUniversity of StrathclydeGlasgowUK
  2. 2.Department of Pharmacy Practice, Faculty of PharmacyKuwait UniversityKuwait CityKuwait

Personalised recommendations